Su1587 Neostigmine and Glycopyrrolate Delivered Transdermally by Iontophoresis Safely Stimulates Bowel Evacuation in Persons With Spinal Cord Injury: A Novel Approach to Bowel Care

2016 ◽  
Vol 150 (4) ◽  
pp. S535
Author(s):  
Mark A. Korsten ◽  
Miroslav Radulovic ◽  
Brian Lyons ◽  
Ravi Vinnakota ◽  
Kamaldeep Singh ◽  
...  
2021 ◽  
Vol 10 (5) ◽  
pp. 1135
Author(s):  
William A. Bauman ◽  
Anton Sabiev ◽  
Shahzad Shallwani ◽  
Ann M. Spungen ◽  
Christopher M. Cirnigliaro ◽  
...  

Persons with spinal cord injury (SCI) have neurogenic bowel disorders characterized by difficulty with evacuation (DWE), fecal incontinence, and discoordination of defecation. Six medically stable in-patients with SCI with a mean age of 57 ± 10 years (range: 39–66 years) and time since injury of 18 ± 17 years (range: 3–47 years) were investigated. Standard of care (SOC) for bowel care was followed by two weeks of SOC plus neostigmine (0.07 mg/kg) and glycopyrrolate (0.014 mg/kg) administered transcutaneously by iontophoresis thrice weekly for two weeks while patients continued to receive SOC. The primary endpoint was time to bowel evacuation. Body weights and abdominal radiographs were obtained. Ten questions related to bowel function and the Treatment Satisfaction Questionnaire for Medication were acquired after each arm. Bowel evacuation time decreased after the dual drug intervention arm (106.9 ± 68.4 vs. 40.8 ± 19.6 min; p < 0.0001). Body weight decreased (2.78 ± 0.98 kg; p < 0.0001), a finding confirmed on abdominal radiograph. Both questionnaires demonstrated improvement after the dual drug intervention arm. No major adverse events occurred. The addition of neostigmine and glycopyrrolate by transcutaneous administration to SOC for bowel care in persons with SCI and DWE resulted in the safe, effective, and predictable bowel evacuation with subjective improvement in bowel care.


2016 ◽  
Vol 27 (3) ◽  
pp. 259-270 ◽  
Author(s):  
Lite Ge ◽  
Kai Liu ◽  
Zhonghua Liu ◽  
Ming Lu

AbstractSpinal cord injury (SCI) is a disastrous injury that leads to motor and sensory dysfunctions in patients. In recent years, co-transplantation has become an increasingly used therapeutic treatment for patients with SCI. Both mesenchymal stem cells (MSCs) and olfactory-ensheathing cells (OECs) have been adopted to ameliorate SCI, with promising outcomes. Remarkable effects on the rehabilitation of patients with SCI have been achieved using MSCs. Olfactory mucosa (OM) MSCs from human OM are one of the most ideal cell resources for auto-transplantation in clinical application owing to their a high proliferation rate and multipotent capability. In addition, OECs derived from OM have been used to improve functional recovery of SCI and resulted in promising functional recovery in years. Accordingly, co-transplantation of OM-MSCs coupled with OM-OECs has been adopted to improve the recovery of SCI. Here we reviewed the reported applications of OM-MSCs and OM-OECs for SCI treatment and proposed that a novel combined strategy using both autologous OM-MSCs and OM-OECs would achieve a better approach for the treatment of SCI.


Spinal Cord ◽  
2014 ◽  
Vol 52 (6) ◽  
pp. 494-498 ◽  
Author(s):  
P M Faaborg ◽  
P Christensen ◽  
A Krassioukov ◽  
S Laurberg ◽  
E Frandsen ◽  
...  

2006 ◽  
Vol 12 (2) ◽  
pp. 160-162 ◽  
Author(s):  
Marinella Galea ◽  
Janine Tumminia ◽  
Lisa M. Garback

Sign in / Sign up

Export Citation Format

Share Document